Novel mutant-enriched sequencing identified high frequency of PIK3CA mutations in pharyngeal cancer

International Journal of Cancer

Volumn 122, Issue 5, 2008, Pages 1189-1194

  Qiu, Wanglong ^a   Tong, Guo Xia ^a   Manolidis, Spiros ^a   Close, Lanny G ^a   Assaad, Adel M ^a   Su, Gloria H ^a  

^a Columbia University College of Physicians and Surgeons ^*  (United States)

Author keywords

HNSCC; Hot spot mutation; Mutant enriched sequencing method; Pharyngeal cancer; PIK3CA oncogene

Indexed keywords

PHOSPHATIDYLINOSITOL 3 KINASE; PIK3CA PROTEIN, HUMAN; PRIMER DNA; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BREAST CANCER; CARCINOGENESIS; CLINICAL ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; DNA SEQUENCE; FEMALE; GENE FREQUENCY; GENE IDENTIFICATION; GENE MUTATION; GENE SEQUENCE; GENE TARGETING; HUMAN; HUMAN TISSUE; MALE; ONCOGENE; PHARYNX CANCER; PIK3CA GENE; PRIORITY JOURNAL; RELIABILITY; SEQUENCE ANALYSIS; SQUAMOUS CELL CARCINOMA; WILD TYPE; GENETICS; METHODOLOGY; MIDDLE AGED; MUTATION; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ADULT; AGED; CARCINOMA, SQUAMOUS CELL; DNA MUTATIONAL ANALYSIS; DNA PRIMERS; FEMALE; HUMANS; MALE; MIDDLE AGED; MUTATION; PHARYNGEAL NEOPLASMS; POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 38749089046     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.23217     Document Type: Article

References (23)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ. Cancer statistics, 2006. CA Cancer J Clin 2006;56:106-30.
2. Carvalho AL, Nishimoto IN, Califano JA, Kowalski LP. Trends in incidence and prognosis for head and neck cancer in the United States: a site-specific analysis of the SEER database. Int J Cancer 2005;114:806-16.
3. Forastiere A, Koch W, Trotti A, Sidransky D. Head and neck cancer. N Engl J Med 2001;345:1890-900.
4. Williams HK. Molecular pathogenesis of oral squamous carcinoma. Mol Pathol 2000;53:165-72.
5. Ma YY, Wei SJ, Lin YC, Lung JC, Chang TC, Whang-Peng J, Liu JM, Yang DM, Yang WK, Shen CY. PIK3CA as an oncogene in cervical cancer. Oncogene 2000;19:2739-44.
6. Shayesteh L, Lu Y, Kuo WL, Baldocchi R, Godfrey T, Collins C, Pinkel D, Powell B, Mills GB, Gray JW. PIK3CA is implicated as an oncogene in ovarian cancer. Nat Genet 1999;21:99-102.
7. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, Yan H, Gazdar A, Powell SM, Riggins GJ, Willson JK, Markowitz S, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 2004;304:554.
8. Kang S, Bader AG, Vogt PK. Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. Proc Natl Acad Sci USA 2005;102:802-7.
9. Lee JW, Soung YH, Kim SY, Lee HW, Park WS, Nam SW, Kim SH, Lee JY, Yoo NJ, Lee SH. PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas. Oncogene 2005;24:1477-80.
10. Campbell IG, Russell SE, Choong DY, Montgomery KG, Ciavarella ML, Hooi CS, Cristiano BE, Pearson RB, Phillips WA. Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res 2004;64:7678-81.
11. Qiu W, Schonleben F, Li X, Ho DJ, Close LG, Manolidis S, Bennett BP, Su GH. PIK3CA mutations in head and neck squamous cell carcinoma. Clin Cancer Res 2006;12:1441-6.
12. Schonleben F, Qiu W, Ciau NT, Ho DJ, Li X, Allendorf JD, Remotti HE, Su GH. PIK3CA mutations in intraductal papillary mucinous neoplasm/carcinoma of the pancreas. Clin Cancer Res 2006;12:3851-5.
13. Samuels Y, Velculescu VE. Oncogenic mutations of PIK3CA in human cancers. Cell Cycle 2004;3:1221-4.
14. Garcia-Rostan G, Costa AM, Pereira-Castro I, Salvatore G, Hernandez R, Hermsem MJ, Herrero A, Fusco A, Cameselle-Teijeiro J, Santoro M. Mutation of the PIK3CA gene in anaplastic thyroid cancer. Cancer Res 2005;65:10199-207.
15. Or YY, Hui AB, To KF, Lam CN, Lo KW. PIK3CA mutations in nasopharyngeal carcinoma. Int J Cancer 2006;118:1065-7.
16. Pedrero JM, Carracedo DG, Pinto CM, Zapatero AH, Rodrigo JP, Nieto CS, Gonzalez MV. Frequent genetic and biochemical alterations of the PI 3-K/AKT/PTEN pathway in head and neck squamous cell carcinoma. Int J Cancer 2005;114:242-8.
17. Woenckhaus J, Steger K, Werner E, Fenic I, Gamerdinger U, Dreyer T, Stahl U. Genomic gain of PIK3CA and increased expression of p110α are associated with progression of dysplasia into invasive squamous cell carcinoma. J Pathol 2002;198:335-42.
18. Kozaki K, Imoto I, Pimkhaokham A, Hasegawa S, Tsuda H, Omura K, Inazawa J. PIK3CA mutation is an oncogenic aberration at advanced stages of oral squamous cell carcinoma. Cancer Sci 2006;97:1351-8.
19. Levi S, Urbano-Ispizua A, Gill R, Thomas DM, Gilbertson J, Foster C, Marshall CJ. Multiple K-ras codon 12 mutations in cholangiocarcinomas demonstrated with a sensitive polymerase chain reaction technique. Cancer Res 1991;51:3497-502.
20. Nakahori S, Yokosuka O, Ehata T, Chuang WL, Imazeki F, Ito Y, Ohto M. Detection of hepatitis B virus precore stop codon mutants by selective amplification method: frequent detection of precore mutants in hepatitis B e antigen positive healthy carriers. J Gastroenterol Hepatol 1995;10:419-25.
21. Bader AG, Kang S, Zhao L, Vogt PK. Oncogenic PI3K deregulates transcription and translation. Nat Rev Cancer 2005;5:921-9.
22. Rogers SJ, Box C, Harrington KJ, Nutting C, Rhys-Evans P, Eccles SA. The phosphoinositide 3-kinase signalling pathway as a therapeutic target in squamous cell carcinoma of the head and neck. Expert Opin Ther Targets 2005;9:769-90.
23. Kim DW, Huamani J, Fu A, Hallahan DE. Molecular strategies targeting the host component of cancer to enhance tumor response to radiation therapy. Int J Radiat Oncol Biol Phys 2006;64:38-46.